Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Istituto Oncologico Veneto IRCCS
FLOWER is a real-world, prospective, observational study enrolling patients with histological and/or cytological diagnosis of EGFR-mutant aNSCLC, receiving first-line treatment with the third-generation EGFR-TKI, osimertinib. All the patients received osimertinib at the recommended dose of 80 mg, orally, once a day. Dosing interruptions or reductions required, based on individual tolerability, were managed according to clinical practice in compliance with label indications.
The FLOWER study aims at evaluating effectiveness, safety, progression pattern and clinical management of untreated EGFR-mutant aNSCLC patients in the real-world.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
histological confirmed diagnosis of NSCLC and EGFR mutation in exon 18-21;
locally advanced inoperable or metastatic disease (stage III and IV according to 8th edition of the TNM classification for lung cancer);
first line treatment with the third generation EGFR TKI, osimertinib;
age \>18 years
written informed consent
You may not be if
Patients who receive study drugs in clinical trials will be excluded.